Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study
Background The prioritized net benefit (Δ) is a measure of the benefit‐risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes. Its estimation requires the classification as Wins or Losses of all possible pairs of patients, one from the exp...
Uložené v:
| Vydané v: | Statistics in medicine Ročník 40; číslo 3; s. 553 - 565 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Hoboken, USA
John Wiley & Sons, Inc
10.02.2021
Wiley Subscription Services, Inc Wiley-Blackwell |
| Predmet: | |
| ISSN: | 0277-6715, 1097-0258, 1097-0258 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
The prioritized net benefit (Δ) is a measure of the benefit‐risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes. Its estimation requires the classification as Wins or Losses of all possible pairs of patients, one from the experimental treatment (E) group and one from the control treatment (C) group. In this simulation study, we assessed the impact of the correlation between prioritized outcomes on Δ, its estimate, bias, size, and power.
Methods
The theoretical Δ value was derived for the specific case of two correlated binary outcomes when a normal copula is used. Focusing on one efficacy and one toxicity outcome, two situations frequently met in practice were simulated: binary efficacy outcome with binary toxicity outcome, or time to event efficacy outcome with categorical toxicity outcome. Several scenarios of efficacy and toxicity were generated, with various levels of correlation.
Results
When E was more effective than C, positive correlations were mainly associated with a decrease in the proportion of Losses, while negative correlations were associated with a decrease in the proportion of Wins on the toxicity outcome. This resulted in an increase of Δ^ with the intensity of the positive correlation without adding any bias. Results were similar whatever the type of outcomes generated but led to power alteration.
Conclusion
Correlations between outcomes analyzed with GPC led to substantial but predictable modifications of Δ and its estimate. Correlations should be taken into consideration when performing sample size estimations in clinical trials. |
|---|---|
| AbstractList | BackgroundThe prioritized net benefit (Δ) is a measure of the benefit‐risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes. Its estimation requires the classification as Wins or Losses of all possible pairs of patients, one from the experimental treatment (E) group and one from the control treatment (C) group. In this simulation study, we assessed the impact of the correlation between prioritized outcomes on Δ, its estimate, bias, size, and power.MethodsThe theoretical Δ value was derived for the specific case of two correlated binary outcomes when a normal copula is used. Focusing on one efficacy and one toxicity outcome, two situations frequently met in practice were simulated: binary efficacy outcome with binary toxicity outcome, or time to event efficacy outcome with categorical toxicity outcome. Several scenarios of efficacy and toxicity were generated, with various levels of correlation.ResultsWhen E was more effective than C, positive correlations were mainly associated with a decrease in the proportion of Losses, while negative correlations were associated with a decrease in the proportion of Wins on the toxicity outcome. This resulted in an increase of Δ^ with the intensity of the positive correlation without adding any bias. Results were similar whatever the type of outcomes generated but led to power alteration.ConclusionCorrelations between outcomes analyzed with GPC led to substantial but predictable modifications of Δ and its estimate. Correlations should be taken into consideration when performing sample size estimations in clinical trials. The prioritized net benefit (Δ) is a measure of the benefit-risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes. Its estimation requires the classification as Wins or Losses of all possible pairs of patients, one from the experimental treatment (E) group and one from the control treatment (C) group. In this simulation study, we assessed the impact of the correlation between prioritized outcomes on Δ, its estimate, bias, size, and power. The theoretical Δ value was derived for the specific case of two correlated binary outcomes when a normal copula is used. Focusing on one efficacy and one toxicity outcome, two situations frequently met in practice were simulated: binary efficacy outcome with binary toxicity outcome, or time to event efficacy outcome with categorical toxicity outcome. Several scenarios of efficacy and toxicity were generated, with various levels of correlation. When E was more effective than C, positive correlations were mainly associated with a decrease in the proportion of Losses, while negative correlations were associated with a decrease in the proportion of Wins on the toxicity outcome. This resulted in an increase of with the intensity of the positive correlation without adding any bias. Results were similar whatever the type of outcomes generated but led to power alteration. Correlations between outcomes analyzed with GPC led to substantial but predictable modifications of Δ and its estimate. Correlations should be taken into consideration when performing sample size estimations in clinical trials. Background The prioritized net benefit (Δ) is a measure of the benefit‐risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes. Its estimation requires the classification as Wins or Losses of all possible pairs of patients, one from the experimental treatment (E) group and one from the control treatment (C) group. In this simulation study, we assessed the impact of the correlation between prioritized outcomes on Δ, its estimate, bias, size, and power. Methods The theoretical Δ value was derived for the specific case of two correlated binary outcomes when a normal copula is used. Focusing on one efficacy and one toxicity outcome, two situations frequently met in practice were simulated: binary efficacy outcome with binary toxicity outcome, or time to event efficacy outcome with categorical toxicity outcome. Several scenarios of efficacy and toxicity were generated, with various levels of correlation. Results When E was more effective than C, positive correlations were mainly associated with a decrease in the proportion of Losses, while negative correlations were associated with a decrease in the proportion of Wins on the toxicity outcome. This resulted in an increase of Δ^ with the intensity of the positive correlation without adding any bias. Results were similar whatever the type of outcomes generated but led to power alteration. Conclusion Correlations between outcomes analyzed with GPC led to substantial but predictable modifications of Δ and its estimate. Correlations should be taken into consideration when performing sample size estimations in clinical trials. The prioritized net benefit (Δ) is a measure of the benefit-risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes. Its estimation requires the classification as Wins or Losses of all possible pairs of patients, one from the experimental treatment (E) group and one from the control treatment (C) group. In this simulation study, we assessed the impact of the correlation between prioritized outcomes on Δ, its estimate, bias, size, and power.BACKGROUNDThe prioritized net benefit (Δ) is a measure of the benefit-risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes. Its estimation requires the classification as Wins or Losses of all possible pairs of patients, one from the experimental treatment (E) group and one from the control treatment (C) group. In this simulation study, we assessed the impact of the correlation between prioritized outcomes on Δ, its estimate, bias, size, and power.The theoretical Δ value was derived for the specific case of two correlated binary outcomes when a normal copula is used. Focusing on one efficacy and one toxicity outcome, two situations frequently met in practice were simulated: binary efficacy outcome with binary toxicity outcome, or time to event efficacy outcome with categorical toxicity outcome. Several scenarios of efficacy and toxicity were generated, with various levels of correlation.METHODSThe theoretical Δ value was derived for the specific case of two correlated binary outcomes when a normal copula is used. Focusing on one efficacy and one toxicity outcome, two situations frequently met in practice were simulated: binary efficacy outcome with binary toxicity outcome, or time to event efficacy outcome with categorical toxicity outcome. Several scenarios of efficacy and toxicity were generated, with various levels of correlation.When E was more effective than C, positive correlations were mainly associated with a decrease in the proportion of Losses, while negative correlations were associated with a decrease in the proportion of Wins on the toxicity outcome. This resulted in an increase of Δ^ with the intensity of the positive correlation without adding any bias. Results were similar whatever the type of outcomes generated but led to power alteration.RESULTSWhen E was more effective than C, positive correlations were mainly associated with a decrease in the proportion of Losses, while negative correlations were associated with a decrease in the proportion of Wins on the toxicity outcome. This resulted in an increase of Δ^ with the intensity of the positive correlation without adding any bias. Results were similar whatever the type of outcomes generated but led to power alteration.Correlations between outcomes analyzed with GPC led to substantial but predictable modifications of Δ and its estimate. Correlations should be taken into consideration when performing sample size estimations in clinical trials.CONCLUSIONCorrelations between outcomes analyzed with GPC led to substantial but predictable modifications of Δ and its estimate. Correlations should be taken into consideration when performing sample size estimations in clinical trials. |
| Author | Maucort‐Boulch, Delphine Ozenne, Brice Buyse, Marc Giai, Joris Péron, Julien Chiêm, Jean‐Christophe |
| Author_xml | – sequence: 1 givenname: Joris orcidid: 0000-0003-2424-8046 surname: Giai fullname: Giai, Joris email: joris.giai@chu-lyon.fr, jorisgiai@gmail.com, jgiai1@chu-grenoble.fr organization: University of Lyon; University Lyon 1; CNRS; UMR 5558 – sequence: 2 givenname: Delphine surname: Maucort‐Boulch fullname: Maucort‐Boulch, Delphine organization: University of Lyon; University Lyon 1; CNRS; UMR 5558 – sequence: 3 givenname: Brice surname: Ozenne fullname: Ozenne, Brice organization: University of Copenhagen – sequence: 4 givenname: Jean‐Christophe surname: Chiêm fullname: Chiêm, Jean‐Christophe organization: International Drug Development Institute – sequence: 5 givenname: Marc surname: Buyse fullname: Buyse, Marc organization: Hasselt University – sequence: 6 givenname: Julien orcidid: 0000-0002-1709-5152 surname: Péron fullname: Péron, Julien organization: Hospices Civils de Lyon |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33140505$$D View this record in MEDLINE/PubMed https://hal.science/hal-03836857$$DView record in HAL |
| BookMark | eNp1kV1vFCEUhompsdvWxF9gSLyxF7MCAwPj3aaxtsm2XlSvCcucaWlmYAWmzfrrZXdrTRq9AXJ4zns-3iN04IMHhN5RMqeEsE_JjXMllXqFZpS0siJMqAM0I0zKqpFUHKKjlO4JoVQw-QYd1jXlRBAxQ5tryHgFHnqXsfM43wFeR0jgLeDQYxtihMFk6ErYheiy-1XeYco2jJDwlJy_xbdFIJph97U2Lj66BCV1XJvoUvDpM17g0uNUhFzwOOWp25yg170ZErx9uo_Rj_Mv388uquW3r5dni2VlOW9VpSxdKdbVbadq2kBvuenrlrdUWQuCN7KWStpeAiiQUgHfntJ2nJHW8gbqY3S6170zgy4zjCZudDBOXyyWehsjtaobJeQDLezHPbuO4ecEKevRJQvDYDyEKWnGhWRSMaUK-uEFeh-m6MskhZKCCSratlDvn6hpNUL3XP-PAX8r2hhSitA_I5Torbe67E1vvS3o_AVqXd4tNEfjhn8lVPuERzfA5r_C-ubyasf_BrLttPM |
| CitedBy_id | crossref_primary_10_1016_j_cct_2021_106400 crossref_primary_10_1002_sim_9690 crossref_primary_10_1002_sim_9648 |
| Cites_doi | 10.1016/S1470-2045(05)70255-2 10.1093/annonc/mdu444 10.18632/oncotarget.12761 10.1093/biostatistics/kxv032 10.1006/jmva.2001.2017 10.2307/1390838 10.1038/bjc.2015.55 10.1007/s11136-005-1579-7 10.1016/S0140-6736(11)60399-1 10.1200/JCO.2006.07.9525 10.1111/j.1539-6924.1999.tb01139.x 10.7326/0003-4819-141-10-200411160-00009 10.1093/jnci/djr128 10.1177/0962280216658320 10.1002/sim.3923 10.1002/pds.3636 10.1200/JCO.2005.06.050 10.1097/MPA.0000000000001234 10.1056/NEJMoa1011923 10.1002/9781118445112.stat08224 10.1001/jamaoncol.2015.6359 10.1056/NEJMoa1304369 10.1093/jnci/djs259 10.1038/bjc.1996.18 |
| ContentType | Journal Article |
| Copyright | 2020 John Wiley & Sons Ltd 2020 John Wiley & Sons Ltd. 2021 John Wiley & Sons, Ltd. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2020 John Wiley & Sons Ltd – notice: 2020 John Wiley & Sons Ltd. – notice: 2021 John Wiley & Sons, Ltd. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION NPM K9. 7X8 1XC |
| DOI | 10.1002/sim.8788 |
| DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Statistics Public Health Mathematics Computer Science |
| EISSN | 1097-0258 |
| EndPage | 565 |
| ExternalDocumentID | oai:HAL:hal-03836857v1 33140505 10_1002_sim_8788 SIM8788 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 123 1L6 1OB 1OC 1ZS 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANLZ AAONW AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABOCM ABPVW ACAHQ ACCFJ ACCZN ACGFS ACPOU ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZVAB BAFTC BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBD EBS EMOBN F00 F01 F04 F5P G-S G.N GNP GODZA H.T H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TN5 UB1 V2E W8V W99 WBKPD WH7 WIB WIH WIK WJL WOHZO WQJ WRC WUP WWH WXSBR WYISQ XBAML XG1 XV2 ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY AMVHM CITATION O8X NPM K9. 7X8 1XC |
| ID | FETCH-LOGICAL-c4498-8c1b82d39d8316efc4af394918cce54673787cf7ee8e778e4e7787cd4209c46e3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000583727100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0277-6715 1097-0258 |
| IngestDate | Tue Oct 14 20:53:49 EDT 2025 Sun Nov 09 11:57:21 EST 2025 Tue Oct 07 05:46:25 EDT 2025 Wed Feb 19 02:30:15 EST 2025 Sat Nov 29 05:32:45 EST 2025 Tue Nov 18 21:21:36 EST 2025 Wed Jan 22 16:30:34 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | clinical trial correlation net benefit generalized pairwise comparisons multivariate analysis |
| Language | English |
| License | 2020 John Wiley & Sons Ltd. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4498-8c1b82d39d8316efc4af394918cce54673787cf7ee8e778e4e7787cd4209c46e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1709-5152 0000-0003-2424-8046 0000-0003-0042-7787 |
| PMID | 33140505 |
| PQID | 2475251599 |
| PQPubID | 48361 |
| PageCount | 13 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03836857v1 proquest_miscellaneous_2457278288 proquest_journals_2475251599 pubmed_primary_33140505 crossref_primary_10_1002_sim_8788 crossref_citationtrail_10_1002_sim_8788 wiley_primary_10_1002_sim_8788_SIM8788 |
| PublicationCentury | 2000 |
| PublicationDate | 10 February 2021 |
| PublicationDateYYYYMMDD | 2021-02-10 |
| PublicationDate_xml | – month: 02 year: 2021 text: 10 February 2021 day: 10 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: England – name: New York |
| PublicationTitle | Statistics in medicine |
| PublicationTitleAlternate | Stat Med |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc Wiley-Blackwell |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc – name: Wiley-Blackwell |
| References | 2011; 377 2011 2004; 141 2013; 369 2006; 15 2014; 25 1996; 73 2002; 82 2012; 104 2016; 17 2014; 23 2018; 27 2005; 23 2011; 103 2016; 7 2016; 2 2010; 29 1999; 19 2020 2015; 112 2019; 48 2005; 6 2013 1990; 110 1992; 1 2011; 364 2007; 25 e_1_2_7_6_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 PDUFA V Plan (e_1_2_7_4_1) 2013 e_1_2_7_16_1 Lee AJ (e_1_2_7_25_1) 1990 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 Benefit‐Risk Methodology Project (e_1_2_7_5_1) 2011 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Péron J (e_1_2_7_20_1) 2020 e_1_2_7_30_1 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_22_1 e_1_2_7_21_1 |
| References_xml | – year: 2011 – volume: 104 start-page: 982 issue: 13 year: 2012 end-page: 989 article-title: Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review publication-title: J Natl Cancer Inst – volume: 377 start-page: 1749 issue: 9779 year: 2011 end-page: 1759 article-title: Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open‐label, randomised factorial trial publication-title: Lancet – volume: 103 start-page: 763 issue: 9 year: 2011 end-page: 773 article-title: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib publication-title: J Natl Cancer Inst – volume: 15 start-page: 411 issue: 3 year: 2006 end-page: 423 article-title: Analyzing oncology clinical trial data using the Q‐TWiST method: clinical importance and sources for health state preference data publication-title: Qual Life Res – volume: 23 start-page: 1228 issue: 6 year: 2005 end-page: 1236 article-title: Irinotecan plus oxaliplatin and leucovorin‐modulated fluorouracil in advanced pancreatic cancer: a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study publication-title: J Clin Oncol – volume: 112 start-page: 971 issue: 6 year: 2015 end-page: 976 article-title: Assessing the benefit‐risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer publication-title: Br J Cancer – year: 2020 article-title: Unbiased estimate of the net survival benefit in the presence of censored observations publication-title: Biom J – volume: 23 start-page: 667 issue: 7 year: 2014 end-page: 678 article-title: Balancing benefit and risk of medicines: a systematic review and classification of available methodologies publication-title: Pharmacoepidemiol Drug Saf – volume: 82 start-page: 1 issue: 1 year: 2002 end-page: 16 article-title: The meta‐elliptical distributions with given marginals publication-title: J Multivar Anal – volume: 73 start-page: 101 issue: 1 year: 1996 end-page: 105 article-title: Phase II study of gemcitabine in patients with advanced pancreatic cancer publication-title: Br J Cancer – volume: 48 start-page: 275 issue: 2 year: 2019 end-page: 280 article-title: The benefit‐risk balance of nab‐paclitaxel in metastatic pancreatic adenocarcinoma publication-title: Pancreas – volume: 1 start-page: 141 issue: 2 year: 1992 end-page: 149 article-title: Numerical computation of multivariate normal probabilities publication-title: J Comput Graph Stat – volume: 364 start-page: 1817 issue: 19 year: 2011 end-page: 1825 article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer publication-title: N Engl J Med – volume: 2 start-page: 901 issue: 7 year: 2016 end-page: 905 article-title: The net chance of a longer survival as a patient‐oriented measure of treatment benefit in randomized clinical trials publication-title: JAMA Oncol – volume: 369 start-page: 1691 issue: 18 year: 2013 end-page: 1703 article-title: Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine publication-title: N Engl J Med – volume: 6 start-page: 669 issue: 9 year: 2005 end-page: 677 article-title: Chemotherapy‐induced neutropenia and treatment efficacy in advanced non‐small‐cell lung cancer: a pooled analysis of three randomised trials publication-title: Lancet Oncol – volume: 7 start-page: 82953 issue: 50 year: 2016 end-page: 82960 article-title: An assessment of the benefit‐risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma publication-title: Oncotarget – volume: 110 year: 1990 – volume: 141 start-page: 781 issue: 10 year: 2004 end-page: 788 article-title: Better reporting of harms in randomized trials: an extension of the CONSORT statement publication-title: Ann Intern Med – volume: 25 start-page: 2284 issue: 11 year: 2014 end-page: 2289 article-title: Association between treatment toxicity and outcomes in oncology clinical trials publication-title: Ann Oncol – volume: 17 start-page: 178 issue: 1 year: 2016 end-page: 187 article-title: Large sample inference for a win ratio analysis of a composite outcome based on prioritized components publication-title: Biostatistics – volume: 25 start-page: 1960 issue: 15 year: 2007 end-page: 1966 article-title: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group publication-title: J Clin Oncol – volume: 19 start-page: 1205 issue: 6 year: 1999 end-page: 1214 article-title: On modeling correlated random variables in risk assessment publication-title: Risk Anal – volume: 29 start-page: 3245 issue: 30 year: 2010 end-page: 3257 article-title: Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem publication-title: Stat Med – volume: 27 start-page: 1230 issue: 4 year: 2018 end-page: 1239 article-title: An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring publication-title: Stat Methods Med Res – year: 2013 – year: 2020 ident: e_1_2_7_20_1 article-title: Unbiased estimate of the net survival benefit in the presence of censored observations publication-title: Biom J – ident: e_1_2_7_8_1 doi: 10.1016/S1470-2045(05)70255-2 – ident: e_1_2_7_7_1 doi: 10.1093/annonc/mdu444 – volume-title: Work Package 1 Report: Description of the Current Practice of Benefit‐Risk Assessment for Centralised Procedure Products in the EU Regulatory Network year: 2011 ident: e_1_2_7_5_1 – ident: e_1_2_7_17_1 doi: 10.18632/oncotarget.12761 – ident: e_1_2_7_26_1 doi: 10.1093/biostatistics/kxv032 – volume-title: (FY 2013‐2017): Structured Approach to Benefit‐Risk Assessment in Drug Regulatory Decision‐Making year: 2013 ident: e_1_2_7_4_1 – ident: e_1_2_7_21_1 doi: 10.1006/jmva.2001.2017 – ident: e_1_2_7_19_1 doi: 10.2307/1390838 – ident: e_1_2_7_16_1 doi: 10.1038/bjc.2015.55 – ident: e_1_2_7_29_1 doi: 10.1007/s11136-005-1579-7 – ident: e_1_2_7_30_1 doi: 10.1016/S0140-6736(11)60399-1 – ident: e_1_2_7_14_1 doi: 10.1200/JCO.2006.07.9525 – ident: e_1_2_7_28_1 doi: 10.1111/j.1539-6924.1999.tb01139.x – ident: e_1_2_7_3_1 doi: 10.7326/0003-4819-141-10-200411160-00009 – ident: e_1_2_7_9_1 doi: 10.1093/jnci/djr128 – ident: e_1_2_7_11_1 doi: 10.1177/0962280216658320 – volume-title: U‐Statistics: Theory and Practice year: 1990 ident: e_1_2_7_25_1 – ident: e_1_2_7_10_1 doi: 10.1002/sim.3923 – ident: e_1_2_7_24_1 – ident: e_1_2_7_6_1 doi: 10.1002/pds.3636 – ident: e_1_2_7_23_1 doi: 10.1200/JCO.2005.06.050 – ident: e_1_2_7_18_1 doi: 10.1097/MPA.0000000000001234 – ident: e_1_2_7_13_1 doi: 10.1056/NEJMoa1011923 – ident: e_1_2_7_27_1 doi: 10.1002/9781118445112.stat08224 – ident: e_1_2_7_12_1 doi: 10.1001/jamaoncol.2015.6359 – ident: e_1_2_7_15_1 doi: 10.1056/NEJMoa1304369 – ident: e_1_2_7_2_1 doi: 10.1093/jnci/djs259 – ident: e_1_2_7_22_1 doi: 10.1038/bjc.1996.18 |
| SSID | ssj0011527 |
| Score | 2.3538585 |
| Snippet | Background
The prioritized net benefit (Δ) is a measure of the benefit‐risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using... The prioritized net benefit (Δ) is a measure of the benefit-risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several... BackgroundThe prioritized net benefit (Δ) is a measure of the benefit‐risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using... |
| SourceID | hal proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 553 |
| SubjectTerms | clinical trial Clinical trials Computer Science correlation generalized pairwise comparisons Mathematics multivariate analysis net benefit Statistics |
| Title | Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fsim.8788 https://www.ncbi.nlm.nih.gov/pubmed/33140505 https://www.proquest.com/docview/2475251599 https://www.proquest.com/docview/2457278288 https://hal.science/hal-03836857 |
| Volume | 40 |
| WOSCitedRecordID | wos000583727100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0258 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011527 issn: 0277-6715 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ri9QwEB_cPZED8bG-Vs8jiuin3rVp2iR-W9TlhL1F1IP9Vto0PQtnu2x3T_Svd6ZpK4cKgl_akgcZmpnkN3n8BuCFzHSYShl4qS-NJ0yhvQxnSS-NOTcqiLFay66_kMulWq30h-5UJd2FcfwQw4IbWUY7XpOBp1lz_Is0tCm_Hil04Eawx1FtozHsvf04P1sMewh9wFbapIxlEPXUsz4_7utemYxGX-go5O848ypsbeed-e3_kfgO3OrQJps59bgL12w1gRun3X76BG66VTvmLiNNYJ-wp6Nuvgffl3bLMhwLi3LLyoohVGTr9raSsawumKHAHheIVXNMLmtiR_qB3_Vui4LZhtGR-nN27nit26x1Wm6-lY1lZoh-2LxmM4Yid1HEWEt3ex_O5u8-vznxukgNnhFCK0-ZIFM8D3WuwiC2hRFpEWqhA2WMjQTFwlHEf2StslIqK-gpTS64r42IbfgAxlVd2UfAcqzux4bngU5b904RvRDiEERiOsv9KbzquywxHY05RdO4SBwBM09Q5oR-8xSeDSXXjrrjD2WeY68P2cS1fTJbJJTmo-8eq0heBlM46JUi6Sy8SbiQEScwqLGdIRttkzZc0srWOyoTITxEnxbbeeiUaWgqDNG1Rfg5hZetzvxVxOTT-1N6P_7Xgk9gn9PBG4pa4x_AeLvZ2adw3Vyi_mwOYSRX6rCzlZ98XBan |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ri9QwEB_uIXogPtbX6qlR5PxUr03TJtFPi7rsYXcRvYP7Vto0PQtnu2x3T_Svd6YvOVQQ_NKWPMjQzCS_yeM3AC9kqv1ESs9JXGkcYXLtpDhLOknIuVFeiNUadv1ILhbq9FR_3II3_V2Ylh9iWHAjy2jGazJwWpA-_MUaWhdfXyn04LZhV6AWoXrvvvs0PYmGTYQ-YivtUobSC3ruWZcf9nUvzUbbX-gs5O9A8zJubSae6c3_EvkW3OjwJpu0CnIbtmw5gqvzbkd9BNfbdTvWXkcawR6hz5a8-Q58X9g1S3E0zIs1K0qGYJEtm_tKxrIqZ4ZCe5wjWs0wuaiIH-kHflebNUpma0aH6s_YWcts3WQtk2L1ragtM0P8w_o1mzAUuYsjxhrC27twMn1__HbmdLEaHCOEVo4yXqp45utM-V5ocyOS3NdCe8oYGwiKhqOIAclaZaVUVtBTmkxwVxsRWv8e7JRVaR8Ay7C6GxqeeTppHDxFBEOIRBCL6TRzx_Cy77PYdETmFE_jPG4pmHmMMsf0m8fwbCi5bMk7_lDmOXb7kE1s27NJFFOai957qAJ54Y1hv9eKuLPxOuZCBpzgoMZ2hmy0TtpySUpbbahMgAARvVps536rTUNTvo_OLQLQMRw0SvNXEePPR3N6P_zXgk_h2ux4HsXR0eLDI9jjdAyHYti4-7CzXm3sY7hiLlCXVk86k_kJjgkZrw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9RAEB7aq5SC-OO09bTqKqJPaZPNJrurT4f1aPF6FLXQt5BsNm2gJsflrtL-9c7klxQVBF-SkN1lh2Qm-0129_sA3shE-7GUnhO70jjCZNpJcJR04pBzo7wQm9Xs-lM5m6mzM32yBh-6vTANP0T_w40io_5eU4DbeZrt_2INrfLvewozuHXYEKQhM4CNgy-T02k_idApttIsZSi9oOOedfl-1_bWaLR-QWshfweat3FrPfBM7v-XyQ_gXos32bhxkIewZoshbB63M-pDuNv8t2PNdqQhbBH6bMibH8H1zC5Zgl_DLF-yvGAIFtm83q9kLCszZkja4xLRaoq385L4kW7wulwt0TJbMVpUf87OG2brumge54sfeWWZ6fUPq_dszNDkVkeM1YS3j-F08unbx0On1WpwjBBaOcp4ieKpr1Ple6HNjIgzXwvtKWNsIEgNRxEDkrXKSqmsoKM0qeCuNiK0_jYMirKwT4Cl2NwNDU89HdcJniKCIUQiiMV0krojeNe9s8i0ROakp3EZNRTMPEKbI3rMI3jV15w35B1_qPMaX3tfTGzbh-NpRPdczN5DFcgrbwS7nVdEbYxXERcy4AQHNfbTF2N00pRLXNhyRXUCBIiY1WI_O4039V35Pia3CEBH8LZ2mr-aGH09Oqbz03-t-BI2Tw4m0fRo9vkZbHFahUMSNu4uDJaLlX0Od8wVutLiRRsxPwH0IBkq |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Net+benefit+in+the+presence+of+correlated+prioritized+outcomes+using+generalized+pairwise+comparisons%3A+A+simulation+study&rft.jtitle=Statistics+in+medicine&rft.au=Giai%2C+Joris&rft.au=Maucort-Boulch%2C+Delphine&rft.au=Ozenne%2C+Brice&rft.au=Chi%C3%AAm%2C+Jean-Christophe&rft.date=2021-02-10&rft.eissn=1097-0258&rft.volume=40&rft.issue=3&rft.spage=553&rft_id=info:doi/10.1002%2Fsim.8788&rft_id=info%3Apmid%2F33140505&rft.externalDocID=33140505 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0277-6715&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0277-6715&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0277-6715&client=summon |